AAV-mediated in vivo knockdown of luciferase using combinatorial RNAi and U1i

Gene Therapy

Volumn 18, Issue 9, 2011, Pages 929-935

  Koornneef, A ^a   Van Logtenstein, R ^a   Timmermans, E ^a   Pisas, L ^a   Blits, B ^a   Abad, X ^b,c   Fortes, P ^b   Petry, H ^a   Konstantinova, P ^a   Ritsema, T ^a  

^a Amsterdam Molecular Therapeutics ^*  (Netherlands)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

AAV; in vivo; RNAi; shRNA; U1 interference

Indexed keywords

LUCIFERASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE SILENCING; GENE TARGETING; IN VITRO STUDY; IN VIVO STUDY; MIXED INFECTION; MOUSE; NONHUMAN; POLYADENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; DEPENDOVIRUS; GENE KNOCKDOWN TECHNIQUES; LIVER; LUCIFERASES; MICE; MUSCLES; RNA INTERFERENCE; RNA, SMALL NUCLEAR;

MURINAE;

EID: 80052601221     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.41     Document Type: Article

References (36)

1. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference- based therapeutics. Nature 2009; 457: 426-433.
2. Tiemann K, Rossi JJ. RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med 2009; 1: 142-151.
3. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811. (Pubitemid 28099681)
4. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004; 431: 343-349. (Pubitemid 39265674)
5. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21-23 nucleotide intervals. Cell 2000; 101: 25-33.
6. Grimm D. Small silencing RNAs: state-of-the-art. Adv Drug Deliv Rev 2009; 61: 672-703.
7. Giering JC, Grimm D, Storm TA, Kay MA. Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 2008; 16: 1630-1636.
8. Laurenti E, Barde I, Verp S, Offner S, Wilson A, Quenneville S et al. Inducible gene and shRNA expression in resident hematopoietic stem cells in vivo. Stem Cells 2010; 28: 1390-1398.
9. Grimm D, Pandey K, Kay MA. Adeno-associated virus vectors for short hairpin RNA expression. Methods Enzymol 2005; 392: 381-405. (Pubitemid 40092527)
10. Le Bec C, Douar AM. Gene therapy progress and prospects-vectorology: design and production of expression cassettes in AAV vectors. Gene Therapy 2006; 13: 805-813.
11. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008; 21: 583-593.
12. Grimm D, Kay MA. RNAi and gene therapy: a mutual attraction. Hematology 2007; 2007: 473-481.
13. Judge A, MacLachlan I. Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 2008; 19: 111-124. (Pubitemid 351271512)
14. Rao DD, Senzer N, Cleary MA, Nemunaitis J. Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development. Cancer Gene Ther 2009; 16: 807-809.
15. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537-541. (Pubitemid 44050158)
16. Furth PA, Choe WT, Rex JH, Byrne JC, Baker CC. Sequences homologous to 5¢ splice sites are required for the inhibitory activity of papillomavirus late 3¢ untranslated regions. Mol Cell Biol 1994; 14: 5278-5289.
17. Guan F, Caratozzolo RM, Goraczniak R, Ho ES, Gunderson SI. A bipartite U1 site represses U1A expression by synergizing with PIE to inhibit nuclear polyadenylation. RNA 2007; 13: 2129-2140. (Pubitemid 350127555)
18. Goraczniak R, Behlke MA, Gunderson SI. Gene silencing by synthetic U1 adaptors. Nat Biotech 2009; 27: 257-263.
19. Gunderson SI, Polycarpou-Schwarz M, Mattaj IW. U1 snRNP inhibits pre-mRNA polyadenylation through a direct interaction between U1 70K and poly(A) polymerase. Mol Cell 1998; 1: 255-264. (Pubitemid 128378666)
20. Beckley SA, Liu P, Stover ML, Gunderson SI, Lichtler AC, Rowe DW. Reduction of target gene expression by modified U1 snRNA. Mol Cell Biol 2001; 21: 2815-2825. (Pubitemid 32244925)
21. Liu P, Gucwa A, Stover ML, Buck E, Lichtler A, Rowe D. Analysis of inhibitory action of modified U1 snRNAs on target gene expression: discrimination of two RNA targets differing by a 1 bp mismatch. Nucl Acids Res 2002; 30: 2329-2339. (Pubitemid 34618983)
22. Fortes P, Cuevas Y, Guan F, Liu P, Pentlicky S, Jung SP et al. Inhibiting expression of specific genes in mammalian cells with 5¢ end-mutated U1 small nuclear RNAs targeted to terminal exons of pre-mRNA. Proc Natl Acad Sci USA 2003; 100: 8264-8269. (Pubitemid 36842533)
23. Liu P, Kronenberg M, Jiang X, Rowe D. Modified U1 snRNA suppresses expression of a targeted endogenous RNA by inhibiting polyadenylation of the transcript. Nucl Acids Res 2004; 32: 1512-1517. (Pubitemid 38854751)
24. Sajic R, Lee K, Asai K, Sakac D, Branch DR, Upton C et al. Use of modified U1 snRNAs to inhibit HIV-1 replication. Nucl Acids Res 2007; 35: 247-255. (Pubitemid 46189849)
25. Jankowska A, Gunderson S, Andrusiewicz M, Burczynska B, Szczerba A, Jarmolowski A et al. Reduction of human chorionic gonadotropin beta subunit expression by modified U1 snRNA caused apoptosis in cervical cancer cells. Mol Cancer 2008; 7: 26.
26. Abad X, Vera M, Jung SP, Oswald E, Romero I, Amin V et al. Requirements for gene silencing mediated by U1 snRNA binding to a target sequence. Nucl Acids Res 2008; 36: 2338-2352. (Pubitemid 351567007)
27. Abad X, Razquin N, Abad A, Fortes P. Combination of RNA interference and U1 inhibition leads to increased inhibition of gene expression. Nucl Acids Res 2010; 38: e136.
28. Riviere C, Danos O, Douar AM. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Therapy 2006; 13: 1300-1308. (Pubitemid 44264084)
29. Grimm D, Kay MA. Combinatorial RNAi: a winning strategy for the race against evolving targets? Mol Ther 2007; 15: 878-888. (Pubitemid 46621646)
30. Hemmings-Mieszczak M, Dorn G, Natt FJ, Hall J, Wishart WL. Independent combinatorial effect of antisense oligonucleotides and RNAi-mediated specific inhibition of the recombinant Rat P2X3 receptor. Nucl Acids Res 2003; 31: 2117-2126. (Pubitemid 37442079)
31. Jarczak D, Korf M, Beger C, Manns MP, Kruger M. Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons. FEBS J 2005; 272: 5910-5922. (Pubitemid 41689362)
32. Grunweller A, Hartmann RK. Expanding RNA silencing approaches by U1 adaptors. ChemBioChem 2009; 10: 1599-1601.
33. Will CL, Luhrmann R. Protein functions in pre-mRNA splicing. Curr Opin Cell Biol 1997; 9: 320-328. (Pubitemid 27263172)
34. Blits B, Derks S, Twisk J, Ehlert E, Prins J, Verhaagen J. Adeno-associated viral vector (AAV)-mediated gene transfer in the red nucleus of the adult rat brain: comparative analysis of the transduction properties of seven AAV serotypes and lentiviral vectors. J Neurosci Methods 2010; 185: 257-263.
35. Smith RH, Levy JR, Kotin RM. A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol Ther 2009; 17: 1888-1896.
36. Ruijter J, Thygesen H, Schoneveld O, Das A, Berkhout B, Lamers W. Factor correction as a tool to eliminate between-session variation in replicate experiments: application to molecular biology and retrovirology. Retrovirology 2006; 3: 2.